19 April 2022 : Clinical Research
Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China
Qing-Qing Zhu1BCDE, Jie Wang23BCDE, Napoleon Bellua Sam4F, Jie Luo5F, Jie Liu1A, Hai-Feng Pan23A*DOI: 10.12659/MSM.935334
Med Sci Monit 2022; 28:e935334
Table 1 Patient awareness of multidrug-resistant tuberculosis and rifampicin-resistant tuberculosis.
Awareness rate (%) | |
---|---|
Could MDR/RR-TB be cured? | 76.0 |
Is MDR/RR-TB more severe and difficult to cure than ordinary tuberculosis? | 92.5 |
If MDR/RR-TB infects others, will they also become MDR/RR-TB once they fall ill? | 64.8 |
Do the drugs to treat MDR/RR-TB have any adverse effects on humans? | 79.4 |
Can I reduce the dose or type of medication at will? | 89.0 |
Can I stop treatment when I feel that my symptoms have subsided? | 82.2 |
Should I stop smoking and drinking if have MDR/RR-TB? | 94.5 |
Is MDR/RR-TB hereditary? | 92.0 |
Which institution should I go to for medical service of MDR/RR-TB? | 59.0 |